Sun Pharma To Acquire Minority Stakes In Two Companies
Sun Pharmaceutical Industries Ltd. inked agreements to acquire minority stakes in Ezerx Health Tech Ltd. and Agatsa Software Ltd.
“The company entered into agreements to acquire minority stakes in the entities, which are non-material investments in allied areas,” it said in its exchange filing.
The pharma giant will acquire 37.76% equity in Ezerx Health Tech for Rs 28.69 crore and a 4.04% stake in Agatsa Software for Rs 4.5 crore.
Sun Pharma increased its investment in Agatsa Software by 4.04% from their previous agreement to acquire 26.09%. The drug maker will own 30.13% of the early-stage digital diagnostic devices company after this acquisition.
The acquisition of shares in Ezerx Health Tech and Agatsa Software is expected to be completed by October 2023 and December 2023, respectively.
Ezerx Health Tech engages in the production, marketing, and distribution of non-invasive diagnostic and ancillary medical devices, while Agatsa Software is an early-stage digital diagnostic device company.
The drugmaker earlier said that it aims to spend 7-8% of its sales in the current fiscal on research and development activities to further strengthen its product portfolio across therapeutic segments. It also expects high single-digit consolidated topline growth for FY24.
Shares of Sun Pharmaceutical closed 0.42% lower at Rs 1119.10, compared to a 0.56% rise in the benchmark NSE Nifty 50.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
